ArticleBMC pediatrics2026
Evaluation of drugs and risk factors requiring therapeutic drug monitoring in the Neonatal Intensive Care Unit: a retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonates in the Neonatal Intensive Care Units (NICU) often receive medications requiring therapeutic drug monitoring (TDM) due to their immature organ function and the narrow therapeutic windows of these drugs. Despite its critical role in optimizing dosing and minimizing toxicity, data on the prevalence and risk factors associated with TDM-requiring drugs in neonates is limited. This study aims to estimate the potential burden of TDM-requiring drug use in a NICU where routine TDM is not implemented and to identify key clinical and demographic factors associated with their use.
methodsA retrospective, descriptive study was conducted on neonates admitted to a NICU between January 1, 2019, and July 1, 2024. Patients who received at least one TDM-requiring drug were included. The drugs included in the patients' treatments that required TDM were accepted as antibiotics (vancomycin, gentamicin, amikacin), antiepileptics (phenytoin, phenobarbital, carbamazepine, valproic acid, levetiracetam) and digoxin. Data were analyzed using chi-square, Mann-Whitney U, Kruskal-Wallis, and binary logistic regression tests.
resultsAmong 3754 neonates, 1404 (37.4%) received TDM-requiring drugs, with 1375 meeting inclusion criteria. The most commonly TDM-requiring drugs were gentamicin (62.5%), vancomycin (13.6%), and amikacin (11.5%). Risk factors significantly associated with TDM included mechanical ventilation (OR = 4.3, 95% CI: 3.2-5.5), total parenteral nutrition (OR = 4.0, 95% CI: 3.1-5.2), and NICU hospitalization ≥ 10 days (OR = 7.3, 95% CI: 5.4-9.9).
conclusionA substantial proportion of neonates in the NICU are exposed to medications requiring TDM. In a setting where routine TDM is not implemented, this finding highlights a potential unmet need for monitoring. Mechanical ventilation, prolonged NICU hospitalization, and total parenteral nutrition were identified as key risk factors. Identifying these high-risk groups may support targeted monitoring strategies and optimize resource allocation in NICUs where TDM is not routinely available.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.